


WHAT IS CLAIMED IS:

1. A compound having the formula:



wherein

- 5 Y is a member selected from C, CH and N;
Z is a member selected from C, CH and B;
R¹ is a member selected from H, acyl, OR⁹, SR⁹, NHNH₂, NR⁹R¹⁰, =O and =NR⁹,

wherein

- 10 R⁹ and R¹⁰ are members independently selected from H, substituted or unsubstituted alkyl, acyl, substituted or unsubstituted heteroalkyl and substituted or unsubstituted aryl;
R² is present or absent and is a member selected from H, acyl, substituted or unsubstituted alkyl, OR¹¹, SR¹¹, NR^{11a}, NR^{12a}, halogen, and =O, wherein R¹¹ is a member selected from H, substituted or unsubstituted alkyl,
15 substituted or unsubstituted heterocycloalkyl, and substituted or unsubstituted heteroaryl;
R^{11a} and R^{12a} are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl and substituted or unsubstituted
20 heteroaryl;
R³ is a member selected from H, acyl, substituted or unsubstituted alkyl, NR¹²R¹³, NR¹²OR¹³, SR¹², (=O) and OR¹², wherein R¹² and R¹³ are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl,

substituted or unsubstituted aryl and substituted or
unsubstituted heteroaryl;

R⁴ and R^{4a} are members independently selected from H, halogen, OMe and OH;

R⁵ and R⁶ are members independently selected from H, and OR¹⁴, wherein

R¹⁴ is a member selected from H, substituted or unsubstituted alkyl, acyl,
substituted or unsubstituted heteroalkyl, substituted or unsubstituted
aryl and P(O)(R¹⁵)(R¹⁶), wherein


R¹⁵ and R¹⁶ are members independently selected from OR¹⁷,
NR¹⁷R¹⁸, OCH₂CH₂CN, substituted or unsubstituted
alkyl and substituted or unsubstituted nucleosides,
wherein

R¹⁷ and R¹⁸ are members independently selected
from H, substituted or unsubstituted
alkyl, substituted or unsubstituted
heteroalkyl, substituted or unsubstituted
aryl and substituted or unsubstituted
heteroaryl,


wherein a member selected from R⁵ and R³; R⁶ and R³; and R¹⁵ and R¹⁶ together with
the atoms to which they are attached are optionally joined to form a ring
system selected from substituted or unsubstituted cycloalkyl and substituted or
unsubstituted heterocycloalkyl;

R⁷ and R⁸ are either present or absent and are independently selected from H, acyl,
substituted or unsubstituted alkyl, and R¹ and R⁸, together with the atoms to
which they are attached are optionally joined into a ring system selected from
substituted or unsubstituted cycloalkyl and substituted or unsubstituted
heterocycloalkyl.

2. The compound according to claim 1, having the formula:




3. The compound according to claim 1, having the formula:




4. The compound according to claim 3, wherein R¹¹ is a member selected from silyl groups and substituted or unsubstituted alkyl ethers.

5. The compound according to claim 1, having the formula:



6. The compound according to claim 5, having the formula:




wherein


R^{19} , R^{20} , and R^{21} are members independently selected from H, acyl and substituted or unsubstituted alkyl.

5

7. The compound according to claim 5, having the formula:



8. The compound according to claim 1, wherein R^6 has the formula:



in which

10

R^{22} is a member selected from substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl;


L is a linker selected from substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl; and

Ar is a member selected from substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl.

15

9. The compound according to claim 8, wherein L comprises a moiety that is cleaved *in vivo* after entry of said compound into a cell.

10. The compound according to claim 1, wherein R⁶ has the formula:



in which

R²² is a member selected from substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl;

L is a linker selected from substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl; and

n is an integer from 1 to 30.

11. The compound according to claim 10, wherein L comprises a moiety that is cleaved *in vivo* after entry of said compound into a cell.

12. A formulation of the compound according to claim 1, and a second compound having the formula:



wherein

A is a hydrophobic domain; and

B is a hydrophilic domain covalently bound to A.

13. The formulation according to claim 12, further comprising a polycationic species.

14. The formulation according to claim 13, wherein said polycationic species is a dendrimeric polyamine.

15. The formulation according to claim 12, wherein said formulation is an aqueous formulation.

16. A method for treating a viral disease comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound according to claim 1.

17. The method of claim 16, wherein said compound is given orally.
18. The method of claim 17, wherein said compound is an enteric formulation.
19. The method of claim 18, wherein said compound is delivered in an oral osmotic drug delivery device.
20. The method of claim 16, wherein the viral disease is caused by a virus that is a member selected from RNA virus and DNA virus.
21. The method of claim 16, wherein the viral disease is caused by a retrovirus.
22. The method of claim 21, wherein the viral disease is caused by HIV.
23. The method of claim 22, wherein the HIV is resistant to nucleotide reverse transcriptase inhibitors.
24. The method of claim 16, wherein the viral disease is caused by a virus of the Flaviviridae family.
25. The method of claim 24, wherein the viral disease is hepatitis C.
26. The method of claim 16, wherein the viral disease is caused by a virus of the Paramyxoviridae family.
27. The method of claim 20, wherein the DNA virus is hepatitis B virus.
28. The method of claim 20, wherein the DNA virus is smallpox/vaccinia virus.